← GLP-1 receptor agonists × glycemic control

TrialJournal of diabetes investigation2016

Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36-week, randomized, double-blind, parallel-group trial.

Yutaka Seino et al.PubMed ↗Full text ↗Publisher ↗

The primary results report of NCT01572740. Its numbers are set against the trial’s posted results below.

  • Liraglutide plus insulinlooks good hereHigher long-term blood sugar, lower long-term blood sugar, lower insulin dose after 36 weeks.Randomised, small.

What the trial testedrandomised · 257 people · 2016

Randomised vs insulin monotherapy (placebo)

Probably raised long-term blood sugar

51×17× to 154×

liraglutide plus insulin vs insulin monotherapy (placebo)

Bigger than almost all for glycemic control

As reported

OR 50.57, 95% CI 16.6–154 · the paper's word: achieved a glycosylated hemoglobin target of <7.0% (<53 mmol/mol) at week 16

Not counted

Probably lowered long-term blood sugar

−1.30percentage points−1.47 to −1.13

liraglutide plus insulin vs insulin monotherapy

As reported

difference −1.30 %, 95% CI −1.47 to −1.13 · the paper's word: glycosylated hemoglobin after 16 weeks

Not counted

Probably lowered insulin dose after 36 weeks

−18%−24% to −10%

liraglutide plus insulin vs insulin monotherapy (placebo)

Bigger than 1 in 10 for glycemic control

As reported

IRR 0.82, 95% CI 0.76–0.90

Against the trial’s posted results

  • Same as the trial’s posted resultThis paper difference −1.30 (−1.47 to −1.13)Posted, primary outcome difference −1.30 (−1.47 to −1.13), p <0.0001Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 16

Who was studied, and how

257people with obesity, in this paper

The trial randomly assignedassigned by chance

liraglutide plus insulin
insulin monotherapy

Probably lowered long-term blood sugar−1.30

randomised

The trial randomly assignedassigned by chance

liraglutide plus insulin
insulin monotherapy (placebo)

Probably raised long-term blood sugar51×

Probably lowered insulin dose after 36 weeks−18%

randomised

the abstract, start to end

… hemoglobin after 16 weeks of -1.30% (-14 mmol/mol; 95% confidence …

… at week 16 (estimated odds ratio 50.57; 95% confidence interval 16.59 …

… the placebo (estimated treatment ratio: 0.82 [95% confidence interval …

← favours treatmentfavours comparator →
could be chance
Glycosylated hemoglobin after 16 weeksliraglutide plus insulin vs insulin monotherapy
−1.30−1.47 to −1.13
Achieved a glycosylated hemoglobin target of <7.0% (<53 mmol/mol) at week 16liraglutide plus insulin vs insulin monotherapy (placebo)
OR 50.5716.6–154
Insulin dose after 36 weeksliraglutide plus insulin vs insulin monotherapy (placebo)
IRR 0.820.76–0.90
GLP-1 receptor agonistsInsulinGlycemic control

GLP-1 receptor agonists × glycemic controlhelps?replicated

unlikelylikely
0.900.90 without it

Insulin × glycemic controlhelps?mixed

unlikelylikely
0.500.50 without it
← favours comparatorfavours treatment →
this papermore certainless certain
1 / 7

36 papers cite it

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

NCT01572740phase 3257 enrolled2012this paper is its primary report
Full record →Abstract, authors, funding and every citing paper · PMID 27182042